AVDL - Avadel Pharmaceuticals plc
IEX Last Trade
15.17
0.280 1.846%
Share volume: 2,203,199
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$14.89
0.28
1.88%
Fundamental analysis
35%
Profitability
23%
Dept financing
25%
Liquidity
75%
Performance
39%
Performance
5 Days
-8.06%
1 Month
-6.59%
3 Months
-3.74%
6 Months
-10.76%
1 Year
-10.76%
2 Year
-10.76%
Key data
Stock price
$15.17
DAY RANGE
N/A - N/A
52 WEEK RANGE
$13.42 - $19.09
52 WEEK CHANGE
-$0.11
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Gregory Divis
Region: US
Website: https://www.avadel.com/
Employees: 144
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.avadel.com/
Employees: 144
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.
Recent news